3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
9
Oxaliplatin
6
Cisplatin
6
Capecitabine
6
durvalumab
4
apatinib
4
S 1 (combination)
4
Irinotecan
4
Immune Checkpoint Inhibitors
4
surufatinib
3
Injections
3
Drug Therapy
3
pembrolizumab
2
lenvatinib
2
camrelizumab
2
Taxes
2
Leucovorin
2
Fluorouracil
2
Docetaxel
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
toripalimab
1
taxane
1
spartalizumab
1
sintilimab
1
regorafenib
1
manganese chloride
1
irinotecan sucrosofate
1
gimeracil
1
gemcitabine-oxaliplatin regimen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Biliary Tract Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled